search
Back to results

Light Therapy on Major Depression Disorder

Primary Purpose

Depressive Disorder

Status
Completed
Phase
Not Applicable
Locations
Taiwan
Study Type
Interventional
Intervention
Light therapy
Sponsored by
Mackay Memorial Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Depressive Disorder

Eligibility Criteria

20 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Fulfill diagnosis of Major depression disorder based on Diagnostic and Statistical Manual of Mental Disorders(DSM-V) for at least 6 weeks and under medication treatment for at least 4 weeks.
  2. at least 20 years old
  3. Hamilton Depression Rating Scale(HAMD-17) >= 13
  4. No medication change for at least 4 weeks and no medication change will be considered in the next 8 weeks.
  5. Agree to participate in this study and sign the permit.

Exclusion Criteria:

  1. Seasonal depression disorder
  2. Other psychological or neurological disorder
  3. Drug or alcohol abuse within 30 days
  4. Visual problem
  5. Light-induced seizure or migraine
  6. Contraindication for MRI study
  7. Severe illness and might be admitted in the near future
  8. Might have a long trip in the near future

Sites / Locations

  • Mackay Memorial Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

Bright treatment light

Red light

Arm Description

Outcomes

Primary Outcome Measures

Change from Baseline Hamilton Depression Rating Scale(HAM-D) at 1,2,4,8 weeks
Determine severity of depression (scores: 0-50) Depressed Mood (sadness, hopeless, helpless, worthless) (0-4 scores) Feelings of Guilt(0-4 scores) Suicide(0-4 scores) Insomnia - Early(0-2 scores) Insomnia - Middle(0-2 scores) Insomnia - Late(0-2 scores) Work and Activities(0-4 scores) Retardation (slowness of thought and speech; impaired ability to concentrate; decreased motor activity)(0-4 scores) Agitation(0-2 scores) Anxiety - Psychic(0-4 scores) Anxiety - Somatic(0-4 scores) Somatic Symptoms - Gastrointestinal(0-2 scores) Somatic Symptoms - General(0-2 scores) Genital Symptoms(0-2 scores) Hypochondriasis(0-4 scores) Loss of Weight(0-2 scores) Insight(0-2 scores) Scores below 7 generally represent the absence or remission of depression. Scores between 7-17 represent mild depression. Scores between 18-24 represent moderate depression. Scores 25 and above represent severe depression.
Change from Baseline Montgomery-Asberg Depression Rating Scale(MADRS) at 1,2,4,8 weeks
Higher MADRS score indicates more severe depression, and each item yields a score of 0 to 6. The overall score ranges from 0 to 60. The questionnaire includes questions on the following symptoms 1. Apparent sadness 2. Reported sadness 3. Inner tension 4. Reduced sleep 5. Reduced appetite 6. Concentration difficulties 7. Lassitude 8. Inability to feel 9. Pessimistic thoughts 10. Suicidal thoughts 0 to 6 - normal /symptom absent 7 to 19 - mild depression 20 to 34 - moderate depression >34 - severe depression
Change from Baseline Clinical Global Impression-Severity(CGI-S) at 1,2,4,8 weeks
The Clinical Global Impression - Severity scale (CGI-S) is a 7-point scale that requires the clinician to rate the severity of the patient's illness at the time of assessment, relative to the clinician's past experience with patients who have the same diagnosis. Possible ratings are: Normal, not at all ill Borderline mentally ill Mildly ill Moderately ill Markedly ill Severely ill Among the most extremely ill patients
Change from Baseline Patient Health Questionnaire(PHQ-9) at 1,2,4,8 weeks
Depression screening by a nine-item in adults Over the last two weeks, how often have you been bothered by any of the following problems? (Scores: 0-27) 0:Not at all, 1:Several days, 2:More than half the days, 3:Nearly every day Little interest or pleasure in doing things Feeling down, depressed, or hopeless Trouble falling or staying asleep, or sleeping too much Feeling tired or having little energy Poor appetite or overeating Feeling bad about yourself, or that you are a failure, or have let yourself or your family down Trouble concentrating on things, such as reading the newspaper or watching television Moving or speaking so slowly that other people could have noticed? Or the opposite, being so fidgety or restless that you have been moving around a lot more than usual Thoughts that you would be better off dead or of hurting yourself in some way 0-4:No depression, 5-9:Mild, 10-14:Moderate, 15-19:Moderately severe, 20-27: Severe

Secondary Outcome Measures

functional MRI
Compare brain resting-state functional MRI change between these two arms. Including measures brain activity by detecting changes associated with blood flow and difference of Resting State Network which is a functionally connected neural network of apparent brain states. Increased strength of the activities or resting state network indicates neural activities are elevated within the regions of the brain or the network. Decreased strength of the activities or resting state network indicates neural activities are diminished within the regions of the brain or the network.
Diffusion Tensor Imaging of MRI
Compare brain Diffusion Tensor Imaging between these two arms. Evaluation the connection or fiber tracts between regions of the brain. Increased strength means enhanced connection between neuronal regions of the brain. Decreased strength means decreased connection between neuronal regions of the brain.

Full Information

First Posted
March 27, 2019
Last Updated
February 12, 2022
Sponsor
Mackay Memorial Hospital
Collaborators
National Tsing Hua University,Taiwan, Ministry of Science and Technology, Taiwan
search

1. Study Identification

Unique Protocol Identification Number
NCT03941301
Brief Title
Light Therapy on Major Depression Disorder
Official Title
Light Therapy on Major Depression Disorder
Study Type
Interventional

2. Study Status

Record Verification Date
February 2022
Overall Recruitment Status
Completed
Study Start Date
June 1, 2019 (Actual)
Primary Completion Date
June 30, 2020 (Actual)
Study Completion Date
June 30, 2020 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Mackay Memorial Hospital
Collaborators
National Tsing Hua University,Taiwan, Ministry of Science and Technology, Taiwan

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No

5. Study Description

Brief Summary
Background: Major depression disorder is a common psychological disease. It is the second-ranked cause of disability worldwide. The pathophysiology is not yet understood. The main theory is monoaminergic theory based on the effect of monoaminergic drugs. Current treatment includes psychotherapy, medication and electroconvulsive therapy. The onset of action for antidepressant is often slow, therefore strategies to improve the outcome are important. Bright light therapy has been found to be effective in reducing the severity of depression not only in seasonal affective disorder but also in other affective disorder. Previous meta-analyses of light therapy for non-seasonal major depression, however, has yielded conflicting evidence for efficacy. Purpose: To investigate possible imaging biomarkers of major depression disorder To evaluate the effect of light therapy on depression Materials and Methods: This prospective study will recruit 100 patients, randomized into 2 study groups: (1) antidepressant plus treatment light, and (2) antidepressant plus placebo light. All patients will accept a thorough psychological evaluation (including Hamilton Depression Rating Scale, Montgomery-Asberg Depression Rating Scale, Clinical Global Impression-Severity and Patient Health Questionnaire-9 items) at baseline and at the 1st, 2nd, 4th, 8th week during the 8-week experiment intervention, by a blind assessor. Morningness- Eveningness Questionnaire-Self-Assessment Version (MEQ-SA) was only evaluated at baseline. Adverse events were evaluated at baseline, 2nd,4th,8th weeks. MRI study will be arranged at baseline and in 4-week experiment. Predicted Results and Influence: To evaluate the additional effect of the treatment light on depression disorder To compare the difference of functional magnetic resonance imaging(fMRI), structural MRI among the two groups and between the patients with and without treatment effect in order to detect imaging biomarkers.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Depressive Disorder

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigator
Allocation
Randomized
Enrollment
43 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Bright treatment light
Arm Type
Experimental
Arm Title
Red light
Arm Type
Placebo Comparator
Intervention Type
Device
Intervention Name(s)
Light therapy
Intervention Description
Participants will be exposed to bright treatment light or red light 30 minutes every day for 4 weeks.
Primary Outcome Measure Information:
Title
Change from Baseline Hamilton Depression Rating Scale(HAM-D) at 1,2,4,8 weeks
Description
Determine severity of depression (scores: 0-50) Depressed Mood (sadness, hopeless, helpless, worthless) (0-4 scores) Feelings of Guilt(0-4 scores) Suicide(0-4 scores) Insomnia - Early(0-2 scores) Insomnia - Middle(0-2 scores) Insomnia - Late(0-2 scores) Work and Activities(0-4 scores) Retardation (slowness of thought and speech; impaired ability to concentrate; decreased motor activity)(0-4 scores) Agitation(0-2 scores) Anxiety - Psychic(0-4 scores) Anxiety - Somatic(0-4 scores) Somatic Symptoms - Gastrointestinal(0-2 scores) Somatic Symptoms - General(0-2 scores) Genital Symptoms(0-2 scores) Hypochondriasis(0-4 scores) Loss of Weight(0-2 scores) Insight(0-2 scores) Scores below 7 generally represent the absence or remission of depression. Scores between 7-17 represent mild depression. Scores between 18-24 represent moderate depression. Scores 25 and above represent severe depression.
Time Frame
1,2,4,8 weeks.
Title
Change from Baseline Montgomery-Asberg Depression Rating Scale(MADRS) at 1,2,4,8 weeks
Description
Higher MADRS score indicates more severe depression, and each item yields a score of 0 to 6. The overall score ranges from 0 to 60. The questionnaire includes questions on the following symptoms 1. Apparent sadness 2. Reported sadness 3. Inner tension 4. Reduced sleep 5. Reduced appetite 6. Concentration difficulties 7. Lassitude 8. Inability to feel 9. Pessimistic thoughts 10. Suicidal thoughts 0 to 6 - normal /symptom absent 7 to 19 - mild depression 20 to 34 - moderate depression >34 - severe depression
Time Frame
1,2,4,8 weeks.
Title
Change from Baseline Clinical Global Impression-Severity(CGI-S) at 1,2,4,8 weeks
Description
The Clinical Global Impression - Severity scale (CGI-S) is a 7-point scale that requires the clinician to rate the severity of the patient's illness at the time of assessment, relative to the clinician's past experience with patients who have the same diagnosis. Possible ratings are: Normal, not at all ill Borderline mentally ill Mildly ill Moderately ill Markedly ill Severely ill Among the most extremely ill patients
Time Frame
1,2,4,8 weeks.
Title
Change from Baseline Patient Health Questionnaire(PHQ-9) at 1,2,4,8 weeks
Description
Depression screening by a nine-item in adults Over the last two weeks, how often have you been bothered by any of the following problems? (Scores: 0-27) 0:Not at all, 1:Several days, 2:More than half the days, 3:Nearly every day Little interest or pleasure in doing things Feeling down, depressed, or hopeless Trouble falling or staying asleep, or sleeping too much Feeling tired or having little energy Poor appetite or overeating Feeling bad about yourself, or that you are a failure, or have let yourself or your family down Trouble concentrating on things, such as reading the newspaper or watching television Moving or speaking so slowly that other people could have noticed? Or the opposite, being so fidgety or restless that you have been moving around a lot more than usual Thoughts that you would be better off dead or of hurting yourself in some way 0-4:No depression, 5-9:Mild, 10-14:Moderate, 15-19:Moderately severe, 20-27: Severe
Time Frame
1,2,4,8 weeks.
Secondary Outcome Measure Information:
Title
functional MRI
Description
Compare brain resting-state functional MRI change between these two arms. Including measures brain activity by detecting changes associated with blood flow and difference of Resting State Network which is a functionally connected neural network of apparent brain states. Increased strength of the activities or resting state network indicates neural activities are elevated within the regions of the brain or the network. Decreased strength of the activities or resting state network indicates neural activities are diminished within the regions of the brain or the network.
Time Frame
4 weeks
Title
Diffusion Tensor Imaging of MRI
Description
Compare brain Diffusion Tensor Imaging between these two arms. Evaluation the connection or fiber tracts between regions of the brain. Increased strength means enhanced connection between neuronal regions of the brain. Decreased strength means decreased connection between neuronal regions of the brain.
Time Frame
4 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
20 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Fulfill diagnosis of Major depression disorder based on Diagnostic and Statistical Manual of Mental Disorders(DSM-V) for at least 6 weeks and under medication treatment for at least 4 weeks. at least 20 years old Hamilton Depression Rating Scale(HAMD-17) >= 13 No medication change for at least 4 weeks and no medication change will be considered in the next 8 weeks. Agree to participate in this study and sign the permit. Exclusion Criteria: Seasonal depression disorder Other psychological or neurological disorder Drug or alcohol abuse within 30 days Visual problem Light-induced seizure or migraine Contraindication for MRI study Severe illness and might be admitted in the near future Might have a long trip in the near future
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Chun-Chao Huang
Organizational Affiliation
Mackay Memorial Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Mackay Memorial Hospital
City
Taipei
ZIP/Postal Code
10449
Country
Taiwan

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Light Therapy on Major Depression Disorder

We'll reach out to this number within 24 hrs